PTC Therapeutics, Inc. (PTCT) FY2026 Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-07-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
PTC Therapeutics, Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Sale of marketable securities- available for sale → investing reconciliation: $320,593,000.00Sale of marketable securities- equity investments → investing reconciliation: $2,156,000.00investing reconciliation → Purchases of marketable securities- available for sale: $753,250,000.00investing reconciliation → Purchases of marketable securities- equity investments: $5,888,000.00investing reconciliation → Acquisition of product rights and licenses: $3,366,000.00investing reconciliation → Purchases of fixed assets: $2,657,000.00Proceeds from exercise of options → financing reconciliation: $5,349,000.00financing reconciliation → Remaining financing cash flows, net (calculated): $77,763,000.00financing reconciliation → Debt issuance costs related to 2031 Convertible Notes: $822,000.00Net cash used in operating activities → operating reconciliation: $25,311,000.00Non-cash interest expense on liability related to sale of future royalties → operating reconciliation: $65,853,000.00Share-based compensation expense → operating reconciliation: $23,827,000.00Remaining operating cash flows, net (calculated) → operating reconciliation: $19,263,000.00Depreciation and amortization → operating reconciliation: $16,817,000.00Accounts payable and accrued expenses → operating reconciliation: $10,692,000.00Non-cash operating lease expense → operating reconciliation: $1,805,000.00Deferred revenue → operating reconciliation: $811,000.00Amortization of debt issuance costs → operating reconciliation: $770,000.00Unrealized foreign currency transaction losses, net → operating reconciliation: $179,000.00Trade and royalty receivables, net → operating reconciliation: $42,000.00operating reconciliation → Net (loss) income attributable to common stockholders: $51,693,000.00operating reconciliation → Non-cash royalty revenue related to sale of future royalties: $81,684,000.00operating reconciliation → Inventory, net: $18,115,000.00operating reconciliation → Amortization of discounts on investments, net: $5,330,000.00operating reconciliation → Prepaid expenses and other current assets: $4,686,000.00operating reconciliation → Other liabilities: $2,702,000.00operating reconciliation → Unrealized gain on marketable securities - equity investments: $1,104,000.00operating reconciliation → Deposits and other assets: $56,000.00Net cash used in financing activities → financing reconciliation: $73,236,000.00Net cash used in investing activities → investing reconciliation: $442,412,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $1,066,332,000.00Cash sources and uses → Exchange-rate effect: $38,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $525,335,000.00Cash sources and uses → Net cash used in investing activities: $442,412,000.00Cash sources and uses → Net cash used in financing activities: $73,236,000.00Cash sources and uses → Net cash used in operating activities: $25,311,000.00Net (loss) income attributable to common stockholders: -$51,693,000.00Net (loss) income attributable to commonstockholders−$51.69 MDepreciation and amortization: $16,817,000.00Depreciation & amortization+$16.82 MNon-cash operating lease expense: $1,805,000.00Operating lease amortization+$1.81 MNon-cash royalty revenue related to sale of future royalties: -$81,684,000.00Non-cash royalty revenue related to sale of futureroyalties−$81.68 MNon-cash interest expense on liability related to sale of future royalties: $65,853,000.00Non-cash interest expense on liability related to saleof future royalties+$65.85 MUnrealized gain on marketable securities - equity investments: -$1,104,000.00Unrealized equity gain & loss−$1.10 MAmortization of discounts on investments, net: -$5,330,000.00Investment discount & premium−$5.33 MAmortization of debt issuance costs: $770,000.00Debt issuance cost amortization+$770.00 KShare-based compensation expense: $23,827,000.00Stock-based compensation+$23.83 MUnrealized foreign currency transaction losses, net: $179,000.00Unrealized FX gain & loss+$179.00 KInventory, net: -$18,115,000.00Inventories−$18.12 MPrepaid expenses and other current assets: -$4,686,000.00Prepaid & other assets−$4.69 MTrade and royalty receivables, net: $42,000.00Receivables, net+$42.00 KDeposits and other assets: -$56,000.00Deposits & other assets−$56.00 KAccounts payable and accrued expenses: $10,692,000.00Payables & accrued liabilities+$10.69 MOther liabilities: -$2,702,000.00Other operating liabilities−$2.70 MInducement expense related to repurchase of 2026 Convertible Notes: $0.00Deferred revenue: $811,000.00Deferred revenue+$811.00 KRemaining operating cash flows, net (calculated): $19,263,000.00Remaining operating (calculated)+$19.26 MNet cash used in operating activities: -$25,311,000.00. Cash required to fund net payments.Operating cash−$25.31 Moperating reconciliation: $165,370,000.00Proceeds from exercise of options: $5,349,000.00Stock option exercises+$5.35 MProceeds from employee stock purchase plan: $0.00Proceeds from issuance of 2031 Convertible Notes: $0.00Debt issuance costs related to 2031 Convertible Notes: -$822,000.00Debt issuance costs−$822.00 KConversion of the 2026 Convertible Notes: -$0.00Remaining financing cash flows, net (calculated): -$77,763,000.00Remaining financing (calculated)−$77.76 MNet cash used in financing activities: -$73,236,000.00. Cash required to fund net payments.Financing cash−$73.24 Mfinancing reconciliation: $78,585,000.00Purchases of fixed assets: -$2,657,000.00PP&E purchases−$2.66 MPurchases of marketable securities- available for sale: -$753,250,000.00AFS securities purchases−$753.25 MPurchases of marketable securities- equity investments: -$5,888,000.00Marketable securities purchases−$5.89 MSale of marketable securities- available for sale: $320,593,000.00AFS securities sales+$320.59 MSale of marketable securities- equity investments: $2,156,000.00Marketable securities proceeds+$2.16 MAcquisition of product rights and licenses: -$3,366,000.00Intangible asset purchases−$3.37 MNet cash used in investing activities: -$442,412,000.00. Cash required to fund net payments.Investing cash−$442.41 Minvesting reconciliation: $765,161,000.00Cash sources and uses: $1,066,332,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $1,066,332,000.00Beginning cash$1.07 BEnding cash: Cash, cash equivalents, and restricted cash: $525,335,000.00Ending cash$525.34 MExchange-rate effect: -$38,000.00FX effect−$38.00 KCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$51.69M + net operating adjustments $26.38M = operating cash −$25.31MFree cash flow−$27.97 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$541.00 MEnding cash − beginning cash
Chart details

PTC Therapeutics, Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026

Cash flows for Jul 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Jun 30, 2026. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2026
1,066,332,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 25,311,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the operating total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Tangible asset impairment and losses on transactions, net), so Tangible asset impairment and losses on transactions, net and Loss on extinguishment of debt cannot be separated for this quarter. It may combine inflows and outflows.
Net (loss) income attributable to common stockholders
negative 51,693,000 US dollars
Depreciation and amortization
16,817,000 US dollars
Non-cash operating lease expense
1,805,000 US dollars
Non-cash royalty revenue related to sale of future royalties
negative 81,684,000 US dollars
Non-cash interest expense on liability related to sale of future royalties
65,853,000 US dollars
Unrealized gain on marketable securities - equity investments
negative 1,104,000 US dollars
Amortization of discounts on investments, net
negative 5,330,000 US dollars
Amortization of debt issuance costs
770,000 US dollars
Share-based compensation expense
23,827,000 US dollars
Unrealized foreign currency transaction losses, net
179,000 US dollars
Inventory, net
negative 18,115,000 US dollars
Prepaid expenses and other current assets
negative 4,686,000 US dollars
Trade and royalty receivables, net
42,000 US dollars
Deposits and other assets
negative 56,000 US dollars
Accounts payable and accrued expenses
10,692,000 US dollars
Other liabilities
negative 2,702,000 US dollars
Inducement expense related to repurchase of 2026 Convertible Notes
0 US dollars
Deferred revenue
811,000 US dollars
Remaining operating cash flows, net (calculated)
19,263,000 US dollars
Investing activities
negative 442,412,000 US dollars. Net cash used.
Purchases of fixed assets
negative 2,657,000 US dollars
Purchases of marketable securities- available for sale
negative 753,250,000 US dollars
Purchases of marketable securities- equity investments
negative 5,888,000 US dollars
Sale of marketable securities- available for sale
320,593,000 US dollars
Sale of marketable securities- equity investments
2,156,000 US dollars
Acquisition of product rights and licenses
negative 3,366,000 US dollars
Financing activities
negative 73,236,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the financing total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Repurchase of the 2026 Convertible Notes), so Repurchase of the 2026 Convertible Notes and Payments on finance lease principal cannot be separated for this quarter. It may combine inflows and outflows.
Proceeds from exercise of options
5,349,000 US dollars
Proceeds from employee stock purchase plan
0 US dollars
Proceeds from issuance of 2031 Convertible Notes
0 US dollars
Debt issuance costs related to 2031 Convertible Notes
negative 822,000 US dollars
Conversion of the 2026 Convertible Notes
0 US dollars
Remaining financing cash flows, net (calculated)
negative 77,763,000 US dollars
Operating adjustment reconciliation
165,370,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
financing displayed reconciliation
78,585,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
investing gross reconciliation
765,161,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 38,000 US dollars
Ending cash on Sep 30, 2026
525,335,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
1,066,332,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 540,997,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 25,311,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
2,657,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 27,968,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$51.69M + net operating adjustments $26.38M = operating cash −$25.31M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 25,311,000 US dollars minus 2,657,000 US dollars equals negative 27,968,000 US dollars.
PTC Therapeutics, Inc. (PTCT) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!